Clinical trials: Non Hodgkins Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°)
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide, an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL)
- Trial name
- R²-DHAP (NCT02983097)
- Testing
- Rituximab, Cisplatin, Carboplatin
- Where
- 12 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Mantle Cell Lymphoma
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of…
- Trial name
- PCYC-1104-CA (NCT01236391)
- Testing
- PCI-32765
- Where
- 18 sites in United States, Germany and 2 more
- Volunteers
- 115 people
- Sponsor
- Pharmacyclics LLC.
Hematologic Malignancies, Myelogenous Leukemia
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from a related donor.
- Conditions
- Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00144703
- Testing
- Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Dana-Farber Cancer Institute
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma…
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT01614197
- Testing
- Temsirolimus, Etoposide, Cyclophosphamide
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 16 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Lymphoma
Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have mycosis fungoides or Sezary syndrome.
- Trial name
- NCT00005788
- Testing
- aldesleukin
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Non Hodgkin Lymphoma, DLBCL
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and…
- Conditions
- Non Hodgkin Lymphoma, DLBCL, Cardiovascular Diseases, Cardiomyopathies
- Trial name
- CLARITY (NCT07041827)
- Testing
- Cardiovascular assessment
- Where
- Netherlands
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.
- Trial name
- NCT00333008
- Testing
- Doxil, Cyclophosphamide, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Alvin and Lois Lapidus Cancer Institute
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or…
- Trial name
- NCT02238522
- Testing
- ZEN003365
- Where
- 4 sites in United States
- Sponsor
- Zenith Epigenetics
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma, Small Intestine Cancer
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004002
- Testing
- bortezomib
- Where
- 5 sites in United States
- Sponsor
- NYU Langone Health
Lymphoma
Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039351
- Testing
- cyclophosphamide, prednisone, vincristine sulfate
- Where
- 17 sites in Belgium, Egypt and 5 more
- Volunteers
- 32 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hematologic Malignancies, Acute Myeloid Leukemia
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
The purpose of this study is to determine the efficacy and safety of transplanting StemEx® in patients with certain hematological malignancies.
- Conditions
- Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia
- Trial name
- ExCell (NCT00469729)
- Testing
- StemEx®
- Where
- 30 sites in United States, Hungary and 3 more
- Volunteers
- 101 people
- Sponsor
- Gamida Cell -Teva Joint Venture Ltd.
Hodgkin Lymphoma, Non-hodgkin Lymphoma
Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell…
- Trial name
- NCT03925935
- Testing
- AB-205
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Angiocrine Bioscience
Non-Hodgkins Lymphoma
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for…
- Trial name
- NCT01281917
- Testing
- Velcade, Temsirolimus
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Wisconsin, Madison
Non-Hodgkin's Lymphoma
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL
Primary Objective: To determine the toxicity profile and maximum tolerated dose (MTD) of VELCADE when administered in combination with CHOP + Rituximab to patients with previously untreated diffuse large B cell or mantle cell…
- Trial name
- NCT00151320
- Testing
- Bortezomib, CHOP, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 76 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias
Providing Access to Cord Blood Units for Transplants
Background: Cord blood banks have been set up to collect and store umbilical cord blood for transplants. These transplants are used to treat different types of cancer.
- Conditions
- Chronic Myelogous Leukemia/Other Leukemia, Acute Leukemias, MDS/MPS, Multiple Myeloma
- Trial name
- NCT01479582
- Testing
- Access to unlicensed cord blood units
- Sponsor
- National Cancer Institute (NCI)
Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Primary Objective: To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab Secondary Objectives: To determine…
- Conditions
- Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01410513
- Testing
- SAR245409
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.